T1	Participants 47 160	patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus?
T2	Participants 175 204	36 patients treated in France
T3	Participants 286 338	patients with metastatic renal cell carcinoma (mRCC)
T4	Participants 561 626	patients with disease progression after a TKI-everolimus sequence